US-based device company Nevro has secured market authorisation from the European Union (EU) for its HFX iQ spinal cord ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...

The company announced receiving CE Mark Certification in Europe for its HFX iQ spinal cord stimulation system. Nevro raised ...

Nevro Corp (NVRO) has disclosed a new risk, in the Accounting & Financial Operations category. Nevro Corp faces a significant financial risk due to potential declines in its market capitalization, ...

NVRO's third-quarter earnings beat its Zacks Consensus Estimate, while worldwide revenues decline year over year. The company ...

Anthony Petrone’s rating is based on a combination of factors impacting Nevro Corp’s current and future performance. Despite a recent improvement in profitability driven by cost-cutting measures, ...

Nevro (NYSE:NVRO) announced today that it received CE mark in Europe for its HFX iQ spinal cord stimulation (SCS) system.

Nevro shares surged 21% after better-than-expected revenue in its latest quarter. Shares were trading around $6.44. The stock is down 75% on the year.

Q3 2024 Earnings Call Transcript November 11, 2024 Nevro Corp. beats earnings expectations. Reported EPS is $-0.51, ...

Nevro (NYSE:NVRO – Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, ...

Nevro's HFX iQ spinal cord stimulator earned the European Union's CE mark, the company said Nov. 12.

The Redwood City, California-based company said it had a loss of 41 cents per share. Losses, adjusted for non-recurring gains, came to 51 cents per share. The results exceeded Wall Street expectations ...